Bukwang Pharm acquires joint license of Meditoxin Inj for treatment purpose from Eisai
Bukwang Pharm announced that it signed a co-marketing and distribution agreement with Eisai Korea for the co-sales and exclusive distribution license of ‘Meditoxin Inj 200 Units,’ a medical botulinum injection, in Korea.
The owner of Meditoxin Inj 200 Units is Meditox. So far, Eisai Korea had be...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
